Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Cagrilintide vs Eloralintide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Cagrilintide and Eloralintide share the amylin class and carry roughly equivalent evidence (Phase 2/3 / Phase 1/2). On the catalogued data layer Eloralintide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Eloralintide's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Cagrilintide

Phase 2/3

Eloralintide

Phase 1/2

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Cagrilintide Eloralintide
Class Long-acting amylin analog Amylin receptor agonist (investigational)
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Amylin receptor agonist; delays gastric emptying; enhances satiety Long-acting amylin receptor agonist
Route SC injection SC injection
Half-life ~7 days Long-acting (weekly target)
Dosage (research) 0.3-4.5 mg SC weekly (often paired with semaglutide) Trial doses undisclosed
Evidence tier Phase 2/3 Phase 1/2
Research depth 139 indexed (PubMed 75 · CT 45 · EPMC 19) 34 indexed (PubMed 8 · CT 22 · EPMC 4)
Availability Investigational Investigational
Reported risks Nausea; GI effects; long-term data pending Early-stage trials

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Cagrilintide or Eloralintide?

Cagrilintide and Eloralintide share the amylin class and carry roughly equivalent evidence (Phase 2/3 / Phase 1/2). On the catalogued data layer Eloralintide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Eloralintide's evidence base is currently denser.

What is the difference between Cagrilintide and Eloralintide?

Cagrilintide is classed as Long-acting amylin analog; Eloralintide is classed as Amylin receptor agonist (investigational). Reported mechanism: Cagrilintide, Amylin receptor agonist; delays gastric emptying; enhances satiety; Eloralintide, Long-acting amylin receptor agonist. Reported half-life: Cagrilintide, ~7 days; Eloralintide, Long-acting (weekly target). Routes in published studies: Cagrilintide, SC injection; Eloralintide, SC injection.

Which has stronger evidence, Cagrilintide or Eloralintide?

Cagrilintide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cagrilintide is graded Phase 2/3, with 23 cited sources on its reference page and 139 indexed studies. Eloralintide is graded Phase 1/2, with 24 cited sources on its reference page and 34 indexed studies.

Which is more accessible, Cagrilintide or Eloralintide?

Neither Cagrilintide nor Eloralintide is an FDA-approved drug. Catalog status: Cagrilintide, Investigational; Eloralintide, Investigational.

Are Cagrilintide and Eloralintide ever combined?

Cagrilintide and Eloralintide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…